Catheter Precision
VTAK

$0.4650

3.79%

Market Cap: $1.3M

About: Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Employees: 14

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

8% more funds holding

Funds holding: 13 [Q1] → 14 (+1) [Q2]

6% more capital invested

Capital invested by funds: $389K [Q1] → $415K (+$25.2K) [Q2]

1.22% less ownership

Funds ownership: 10.58% [Q1] → 9.36% (-1.22%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VTAK.

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about VTAK published over the past 30 days

Catheter Precision, Inc. Expands LockeT Distribution to Middle East

FORT MILL, SC / ACCESSWIRE / September 18, 2024 / Catheter Precision, Inc. (the"Company") (NYSE American:VTAK), a US based medical device pioneering electrophysiology products, announced that it has completed a distribution agreement for LockeT with Dubai based company Forum Medical. The distribution agreement also includes partnerships with additional distributors in the Middle East, expanding LockeT distribution to Georgia, Uzbekistan and Kazakhstan.

Catheter Precision, Inc. Expands LockeT Distribution to Middle East

Catheter Precision, Inc. (NYSE American: VTAK) Reports First Purchase Order for LockeT in the Pacific Northwest Territory

FORT MILL, SC / ACCESSWIRE / September 11, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company in the growing field of cardiac electrophysiology, announced its first purchase order from the pacific northwest territory. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT.

Catheter Precision, Inc. (NYSE American: VTAK) Reports First Purchase Order for LockeT in the Pacific Northwest Territory

Presentation at European Society of Cardiology Demonstrates VIVO Accuracy in Complex VT Patients

FORT MILL, SC / ACCESSWIRE / September 5, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) today announced that at the recently held European Society of Cardiology (ESC) Symposium, interim results demonstrating the use of VIVO in localizing the site of origin of ventricular tachycardia (VT) for patients with scar related re-entrant VT were presented. Additionally, the presentation showed the relationship to the relevant myocardial scar on cross-sectional imaging from the CT scan.

Presentation at European Society of Cardiology Demonstrates VIVO Accuracy in Complex VT Patients

Catheter Precision, Inc. (NYSE American:VTAK) Reports First Purchase Order for LockeT in a New US Territory

FORT MILL, SC / ACCESSWIRE / September 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, announced its first purchase order from a hospital in the greater Chicago area. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the Chicago region.

Catheter Precision, Inc. (NYSE American:VTAK) Reports First Purchase Order for LockeT in a New US Territory

Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option

FORT MILL, SC / ACCESSWIRE / September 3, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the closing of its previously announced public offering of 805,900 common stock units, including 458,623 common stock units issued upon exercise of the underwriters' over-allotment option, priced at a public offering price of $1.00 per unit, and 2,773,000 pre-funded warrant units, priced at a public offering price of $0.9999 per unit. Each common stock unit and pre-funded warrant unit consists of one share of common stock (or, in lieu of common stock, a pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001), one warrant to purchase one share of common stock that expires on the six month anniversary of the date of issuance (a "Series H Warrant"), one warrant to purchase one share of common stock that expires on the eighteen month anniversary of the date of issuance (a "Series I Warrant"), and one warrant to purchase one share of common stock that expires on the five year anniversary of the date of issuance (a "Series J Warrant").

Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option

Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering

FORT MILL, SC / ACCESSWIRE / August 30, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the pricing of its underwritten public offering of common stock units and pre-funded units for aggregate gross proceeds of approximately $3.1 million prior to deducting underwriting discounts and commissions and offering expenses. The equity offering is comprised of 347,277 common stock units, priced at a public offering price of $1.00 per unit, and 2,773,000 pre-funded warrant units, priced at a public offering price of $0.9999 per unit.

Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering

Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report

FORT MILL, SC / ACCESSWIRE / August 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Financials and Operational Report. Operational highlights include the following: First commercial sales of LockeT in the US 14 new sales and clinical hires at various stages of training completion Larger number of US hospitals than projected have confirmed product interest and have scheduled evaluations 23 hospitals for LockeT 10 hospitals for VIVO VIVO product evaluation started at large volume center in Italy New LockeT publication in the Journal of Cardiovascular Electrophysiology Catheter Precision is attending the Kansas City Heart Rhythm Society Conference (KCHRS) in Kansas City August 17 and 18, 2024 Completion of the VIVO EU Registry in June 2024 2024 Second Quarter Financial Results are as follows: Total assets at June 30, 2024, were $26 million Total cash on position at June 30, 2024 was $16 thousand, and $330 thousand at August 12, 2024 Total revenues for the three and six months ended June 30, 2024, were $93 thousand and $175 thousand, respectively Shareholders' equity as of June 30, 2024, was $14.3 million Net loss for the three and six months ended June 30, 2024, was ($4.2) million and ($6.9) million, respectively LockeT sales for the three and six months ended June 30, 2024, were $38 thousand for both periods.

Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report

Catheter Precision, Inc. Announces Publication of LockeT Data in the Journal of Cardiovascular Electrophysiology

FORT MILL, SC / ACCESSWIRE / August 6, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today the publication of its first LockeT study in the Journal of Cardiovascular Electrophysiology. The study titled, Feasibility, safety and efficacy of a novel external compression vascular closure device: The LockeT Study , was made available online on August 5, 2024.

Catheter Precision, Inc. Announces Publication of LockeT Data in the Journal of Cardiovascular Electrophysiology

Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study

FORT MILL, SC / ACCESSWIRE / July 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that it has enrolled 75 patients in its Phase II LockeT Study, which is now expected to conclude in October 2024. As previously disclosed, the three phases of the LockeT studies began in 2023 and are intended to show the product's safety and benefits.

Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study

Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO

FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began in October 2021 and patient enrollment concluded in June 2023.

Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO

See News Rankings